This report was first published by Endpoints News. To see the original version, click here
Theravance Biopharma will wind down its entire R&D organization and lay off 50% of its overall workforce after another Phase 3 fail for an experimental medicine called ampreloxetine.
The US-Irish drugmaker said Tuesday that ampreloxetine flopped in a late-stage test in patients with symptomatic neurogenic orthostatic hypotension due to multiple system atrophy. The drug failed a Phase 3 in 2021, leading to a 75% workforce reduction at the time. It missed the mark in another Phase 3 in 2022.
您已阅读29%（583字），剩余71%（1405字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。